Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

During the last few months, India's largest drug maker Ranbaxy has been in the news more than almost any other manufacturer. Ranbaxy settled patent disputes on two of the largest global drug brands, Lipitor and Nexium. The company's CEO Malvinder Singh sealed a "game-changer" deal with Japan's third largest drug maker Daiichi Sankyo and sold 34.8 percent of his personal and family stake for over $4 billion (PharmAsia News, June 11, 2008). And a U.S FDA investigation of Ranbaxy continues to heat up over allegations of good manufacturing practices deviations at one of the company's manufacturing sites in India (PharmAsia News, July 29, 2008). This week, PharmAsia News' India bureau sat down with Singh to get his take on the action.

You may also be interested in...



Final Assault: Daiichi Sankyo Threatens Legal Action Against Former Ranbaxy Shareholders For Concealing Information

Breaking its silence after four years, Daiichi Sankyo hinted for the first time that it would pursue legal remedies against former shareholders of Ranbaxy, which the Japanese company bought in 2008 to expand into emerging markets and the generics drug space.

U.S. Congress Expands Probe Into Ranbaxy’s AIDS Drugs Supplied To Developing Nations

MUMBAI - Four leaders of the U.S. Congressional Committee on Energy and Commerce - John Dingell, Bart Stupak, Joe Barton and John Shimkus have expanded their investigations into U.S. FDA's handling of Ranbaxy's anti-AIDS drugs that are supplied to African and other developing nations as part of the President's Emergency Plan for AIDS Relief program

U.S. Congress Expands Probe Into Ranbaxy’s AIDS Drugs Supplied To Developing Nations

MUMBAI - Four leaders of the U.S. Congressional Committee on Energy and Commerce - John Dingell, Bart Stupak, Joe Barton and John Shimkus have expanded their investigations into U.S. FDA's handling of Ranbaxy's anti-AIDS drugs that are supplied to African and other developing nations as part of the President's Emergency Plan for AIDS Relief program

Related Content

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel